Table 2 Baseline (before treatment) disease activity assessment of the JDM cohort
Reference Range | Mean ± SD | Median (range) | |
|---|---|---|---|
Age (years) | 6 ± 3.1 | 5.4 (1.9–16.4) | |
Duration of untreated disease (months) | 9.6 ± 10.2 | 6.5 (1–73) | |
Clinical disease activity indicator | |||
DAS-total | 0 | 11 ± 3.6 | 11.5 (3–19) |
DAS-skin | 0 | 5.9 ± 1.5 | 6 (2–9) |
DAS-muscle | 0 | 5.1 ± 1.5 | 5 (0–10) |
CMAS | 52 | 37 ± 10.3 | 38 (12–52) |
ERL (#/mm) | > 7 | 5 ± 3.1 | 4.9 (2.3–10.3) |
Laboratory disease activity indicators | |||
Neopterin (nmol/L) | < 10 | 19.4 ± 10.6 | 18.5 (2.4–49.3) |
ESR (mm/hr) | < 20 | 19 ± 13.4 | 15 (3–65) |
vWF Antigen | 156 ± 75 | 140 (52–374) | |
Muscle enzymes | |||
CK (IU/L) | 26–27 | 1700 ± 5291 | 140 (57-35471) |
AST (IU/L) | 17–96 | 107 ± 162.5 | 46 (22–890) |
LDH (IU/L) | 147–463 | 455 ± 392.6 | 342 (166–2259) |
Aldolase (U/L) | 3.4–8.6 | 21.6 ± 41.6 | 9.9 (2.8–237) |
Flow cytometry | |||
Total T cells (CD3+) | 64 ± 8.3 | 64 (41–86) | |
T helper cells (CD3 + CD4+) | 44.4 ± 8 | 45 (26–64) | |
T cytotoxic cells (CD3 + CD8+) | 18.6 ± 4.4 | 19 (6–31) | |
B cells (CD19+) | 29 ± 8.3 | 29 (12–52) | |
NK cells (CD16+/CD56+) | 6.3 ± 3.6 | 5 (1–15) |